Evaluating heart damage from radiation in lung and esophageal cancer patients
Official title: PET Functional Imaging to Evaluate Cardiac Radiation Damage (EUCLID)
Run by Thomas Jefferson University · NCT05775939 · Data updated 2026-11-12
This study is testing how radiation treatment for lung and esophageal cancer affects the heart and aims to find ways to reduce heart damage during therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Thomas Jefferson University Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | January 20, 2023 |
| Main results expected | July 1, 2027 |
| Study ends | July 1, 2028 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT05775939 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with pathologically proven lung or esophageal cancer who are scheduled to receive radiation therapy.
✕Probably not a fit
Patients who are receiving palliative radiation doses or have contraindications for FDG PET-CT scans may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial uses PET/CT imaging to assess cardiac radiation damage in patients undergoing treatment for lung or esophageal cancer. Participants will receive fludeoxyglucose F-18 PET-CT scans of the heart before, during, and after radiation therapy to monitor any functional changes. The study aims to identify how these imaging changes correlate with overall survival, cardiac toxicity, and cardiac-related death. Additionally, it explores strategies to minimize cardiotoxicity during radiation treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of cardiac health in cancer patients undergoing radiation therapy.
How similar studies have gone: Other studies have shown promise in using imaging techniques to assess cardiac function in cancer patients, suggesting this approach may be beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged \>= 18 * Life expectancy \>= 3 months as assessed by Radiation Oncologist * Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose) * Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer * Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted Exclusion Criteria: * Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist * Palliative radiation doses defined as 20 Gy in 5 fractions
Where it's running
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Yevgeniy Vinogradskiy — Thomas Jefferson University
- Study coordinator: Yevgeniy Vinogradskiy, MD
- Email: yevgeniy.vinogradskiy@jefferson.edu
- Phone: 215-955-3605
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Vanguard: a new blood test approach to screen for multiple cancers
This study will test two different blood-based multi-cancer detection tests in adults 45–75 without cancer to see if they find cancers earlier than usual care.
-
Imaging study using two antibody fragments in patients with solid tumors
This study is testing two special antibody fragments in people with solid tumors to see how well they target cancer cells and how they move through the body.
-
Collecting data on side effects of proton therapy for cancer treatment
This study is trying to learn about the side effects that cancer patients experience after receiving proton therapy to help improve future treatments.
-
Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread
This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.
-
Couples Coping Together Against Cancer: A Feasibility and Acceptability Look
This observational study tests whether a brokered program for patients with cancer and their partners is feasible and acceptable, and whether it may reduce distress over time.
-
Lung Toolkit: a tailored education program to help AI/AN cigarette smokers learn about lung cancer and screening
A Lung Toolkit education program is tested to see if it improves knowledge about lung cancer and screening among American Indian and Alaska Native cigarette smokers aged 50–80.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.